🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. Nano-crystalline Megestrol Acetate Oral Suspension

    China SXT Pharmaceuticals

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  2. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 3 small molecule active

    8 trials

  3. Nimotuzumab

    Praxis Precision Medicines

    Pancreatic Cancer, Advanced or Metastatic

    phase 3 small molecule completed

    1 trial

  4. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  5. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  6. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  7. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  8. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  9. Nivolumab

    Rein Therapeutics

    Metastatic Kidney Cancer

    phase 3 small molecule active

    1 trial

  10. Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection

    Amgen Technology (Ireland) UC

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  11. ONDANSETRON, IRINOTECAN, CALCIUM FOLINATE, CALCIUM LEVOFOLINATE, FLUOROURACIL, METHYLPREDNISOLONE

    Pari Pharma GmbH

    patient with colorectal cancer with hepatic metastasis

    phase 3 small molecule active

    1 trial

  12. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    oesophageal cancer

    phase 3 small molecule active

    1 trial

  13. OPDIVO 10 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, Tecentriq 1 200 mg concentrate for solution for infusion

    Boehringer Ingelheim International GmbH

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  14. OXALIPLATIN, Bemarituzumab, Placebo for AMG 552, FLUOROURACIL, FOLINIC ACID

    Amgen Technology (Ireland) UC

    Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression

    phase 3 small molecule active

    1 trial

  15. OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, BNT327 20 mg ml, CAPECITABINE, BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BNT327 50 mg ml, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  16. OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL

    Cancer Prevention Pharma (Ireland) Limited

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  17. OXALIPLATIN, FOLINIC ACID, IRINOTECAN, FLUOROURACIL

    Cancer Prevention Pharma (Ireland) Limited

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  18. Obatoclax Mesylate, Carboplatine and Etoposide

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  19. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  20. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  21. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  22. Orteronel

    Takeda Pharmaceuticals International AG

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  23. Oxaliplatin

    First Tracks Biotherapeutics

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  24. PACLITAXEL , BNT327, PEMETREXED , CARBOPLATIN , BNT327, PEMBROLIZUMAB

    BioNTech Manufacturing GmbH

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources